<PAGE>   1
                                                 Filed pursuant to Rule 424(c);
                                                 File Number 333-4105



                         CALYPTE BIOMEDICAL CORPORATION
                  SUPPLEMENT TO PROSPECTUS DATED JULY 26, 1996


        On August 6, 1996, Calypte Biomedical Corporation received a product
license and an establishment license from the FDA to manufacture and sell in
interstate and foreign commerce the Company's urine-based HIV-1 screening test
for use in professional laboratory settings.  In addition, the Company is
required to perform a Phase IV study of paired urine and blood samples from 100
HIV positive women using the Company's screening test and to submit the results
of such study to the FDA.


August 7, 1996



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission